Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

47.35 -0.18 (-0.38%)

Streaming Delayed Price Updated: 2:47 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

42 43 Next >

The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 ↗

July 09, 2024

A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.

Via InvestorPlace

Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows ↗

July 08, 2024

Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between...

Via Benzinga

United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win ↗

July 05, 2024

New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election.

Via Benzinga

Topics ETFs

Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗

July 04, 2024

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Via InvestorPlace

CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts ↗

July 03, 2024

CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs.

Via InvestorPlace

Topics Workforce

CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK ↗

July 03, 2024

CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK.

Via InvestorPlace

GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B ↗

July 03, 2024

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while...

Via Benzinga

3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024 ↗

July 03, 2024

A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses.

Via The Motley Fool

Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims ↗

July 02, 2024

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...

Via Benzinga

Topics Lawsuit

CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK ↗

June 27, 2024

The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further...

Via Benzinga

Why Is Moderna Stock Trading Lower On Wednesday? ↗

June 26, 2024

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in...

Via Benzinga

Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots ↗

June 26, 2024

After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease.

Via Investor's Business Daily

Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗

June 26, 2024

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

Via Benzinga

UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract ↗

June 24, 2024

Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers.

Via Benzinga

Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer ↗

June 20, 2024

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

Via Benzinga

Topics Lawsuit

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

June 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗

June 18, 2024

Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products.

Via Benzinga

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

June 20, 2024

From FN Media Group LLC

Via GlobeNewswire

7 A-Rated Biotech Stocks Worth Betting on in June ↗

June 14, 2024

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.

Via InvestorPlace

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗

June 11, 2024

Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.

Via InvestorPlace

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗

June 10, 2024

If approved, this would be the first combination vaccine based on mRNA technology to hit the market.

Via Investor's Business Daily

US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

June 07, 2024

From GSK plc

Via Business Wire

The 3 Most Undervalued Pharma Stocks to Buy in June 2024 ↗

June 06, 2024

These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.

Via InvestorPlace

Topics Economy

Large Cap BIopharmaceuticals Overview ↗

June 03, 2024

As a defensive play healthcare is weighted at about 12% of the S&P 500.

Via Talk Markets

Topics Stocks

GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know. ↗

June 03, 2024

Investors in GlaxoSmithKline are seeing a lot of red on their screens today, as GSK stock falls more than 8% on big legal news.

Via InvestorPlace

Topics Lawsuit

GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma ↗

June 03, 2024

GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or...

Via Benzinga

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗

June 03, 2024

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...

Via Benzinga

Topics Lawsuit

GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 03, 2024

Via Benzinga

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 03, 2024

Via Benzinga

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

June 03, 2024

From GSK plc

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Starting at $3.75/week.

Subscribe Today